A detailed history of Cubist Systematic Strategies, LLC transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Cubist Systematic Strategies, LLC holds 678,625 shares of VERV stock, worth $3.25 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
678,625
Previous 395,699 71.5%
Holding current value
$3.25 Million
Previous $1.93 Million 70.07%
% of portfolio
0.02%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$4.4 - $7.86 $1.24 Million - $2.22 Million
282,926 Added 71.5%
678,625 $3.28 Million
Q2 2024

Aug 14, 2024

BUY
$4.76 - $12.79 $1.34 Million - $3.6 Million
281,173 Added 245.51%
395,699 $1.93 Million
Q1 2024

May 15, 2024

SELL
$10.81 - $17.96 $317,889 - $528,149
-29,407 Reduced 20.43%
114,526 $1.52 Million
Q4 2023

Feb 14, 2024

BUY
$8.84 - $18.7 $240,757 - $509,294
27,235 Added 23.34%
143,933 $2.01 Million
Q3 2023

Nov 14, 2023

BUY
$11.42 - $20.82 $892,370 - $1.63 Million
78,141 Added 202.66%
116,698 $1.55 Million
Q2 2023

Aug 14, 2023

SELL
$13.34 - $19.9 $1.73 Million - $2.58 Million
-129,569 Reduced 77.07%
38,557 $722,000
Q1 2023

May 15, 2023

BUY
$14.3 - $24.01 $1.59 Million - $2.67 Million
111,004 Added 194.33%
168,126 $2.42 Million
Q4 2022

Feb 14, 2023

BUY
$17.85 - $40.7 $659,307 - $1.5 Million
36,936 Added 182.98%
57,122 $1.11 Million
Q3 2022

Nov 14, 2022

SELL
$15.63 - $41.49 $1.66 Million - $4.4 Million
-105,943 Reduced 84.0%
20,186 $693,000
Q2 2022

Aug 15, 2022

BUY
$11.14 - $23.17 $1.13 Million - $2.36 Million
101,663 Added 415.53%
126,129 $1.93 Million
Q1 2022

May 16, 2022

BUY
$20.92 - $39.36 $511,828 - $962,981
24,466 New
24,466 $558,000
Q4 2021

Feb 14, 2022

SELL
$31.94 - $54.82 $204,607 - $351,176
-6,406 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$46.0 - $73.99 $278,530 - $448,009
6,055 Added 1725.07%
6,406 $301,000
Q2 2021

Aug 16, 2021

BUY
$31.92 - $60.25 $11,203 - $21,147
351 New
351 $21,000

Others Institutions Holding VERV

About Verve Therapeutics, Inc.


  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $287M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track Cubist Systematic Strategies, LLC Portfolio

Follow Cubist Systematic Strategies, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.